Livagen (20MG)

What Is Livagen and Why Buy It for Research?

Buy Livagen 20mg in Switzerland for research into chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation. Specifically, Livagen (also known as KEDA or Lys-Glu-Asp-Ala) is a synthetic tetrapeptide composed of four amino acids with the sequence Lys-Glu-Asp-Ala (KEDA). Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology developed Livagen as the liver-targeted member of the Khavinson peptide bioregulator family. Furthermore, the peptide was designed to represent the proposed active fragment of a larger hepatic peptide extract isolated from liver tissue.

Livagen shares the first two amino acids (Lys-Glu) with the dipeptide Vilon (KE), which researchers separately isolated from thymus extracts and developed as an immunomodulatory bioregulator. Within the Khavinson family, each short peptide serves a specific tissue target: Epithalon for pineal gland, Cortagen for brain cortex, Bronchogen for bronchial epithelium, and Livagen for liver. Livagen has a molecular weight of 461.47 g/mol and the molecular formula C₁₈H₃₁N₅O₉.

In scientific research, Livagen serves as a molecular tool for studying tissue-specific gene expression regulation, chromatin remodeling, and hepatic biology. Furthermore, Core Peptides supplies Livagen as a lyophilized powder in a 20mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy Livagen 20mg in Switzerland.

Livagen Research Overview: Buy Livagen 20mg in Switzerland for Chromatin Studies

Centrally, research into Livagen has focused on its function as a tissue-specific bioregulator targeting the liver and lymphocytes. The Khavinson hypothesis proposes that short peptides cross the cell membrane, reach the nucleus, and modulate chromatin and gene expression in a tissue-selective way. Notably, Livagen’s most distinctive property is its ability to induce chromatin decondensation (de-heterochromatinization) in lymphocytes from elderly individuals, reactivating ribosomal genes and releasing genes that have been silenced by age-related heterochromatinization.

Unlike conventional pharmaceutical agents that act through receptor-mediated signaling, Livagen modulates gene expression through epigenetic mechanisms. Studies have demonstrated that Livagen induces activation of ribosomal genes and causes de-heterochromatinization (activation) of chromatin in cultured lymphocytes from old individuals. Furthermore, the peptide reduces heterochromatin packing in lymphocyte and hepatocyte nuclei from older donors, with a net effect on chromatin accessibility that the originating group interprets as reactivation of silenced genes.

Furthermore, Livagen inhibits enkephalin-degrading enzymes in human serum more effectively than some well-known peptidase inhibitors such as puromycin, leupeptin, and D-PAM. Additionally, the peptide has demonstrated hepatoprotective and immunoprotective effects in animal models of hepatitis and liver fibrosis. Accordingly, researchers who buy Livagen 20mg in Switzerland from Core Peptides can support their investigations into chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation.

How Does Livagen Work in Research?

Mechanistically, Livagen’s proposed action involves functioning as a nuclear-targeting peptide that modulates gene expression through epigenetic chromatin remodeling. The peptide operates through several interconnected mechanisms.

Chromatin Decondensation and Gene Activation

Livagen induces de-heterochromatinization—the unrolling and decondensation of heterochromatin—effectively releasing locked genes for transcriptional activation. Studies have shown that Livagen induces activation of ribosomal genes and causes de-heterochromatinization (activation) of chromatin in cultured lymphocytes. Furthermore, the peptide reduces heterochromatin packing in lymphocyte and hepatocyte nuclei from older donors, with a net effect on chromatin accessibility that the originating group interprets as reactivation of silenced genes. Biophysical work from the same program has proposed that short peptides like Livagen can bind DNA in a sequence-selective way at promoter regions and modulate the transcription of selected target genes.

Hepatocyte Protein Synthesis

Livagen increases the level of protein synthesis in hepatocytes from rats of different ages. Researchers obtained the peptide by directed chemical synthesis based on amino acid analysis of liver polypeptide preparations, and studies have shown that it enhances protein synthesis in cultured hepatocytes. Consequently, this tissue-specific effect supports Livagen’s classification as a liver-targeted bioregulator.

Enkephalinase Inhibition

Livagen inhibits enkephalin-degrading enzymes in human serum, with an IC50 of 20 µM. Notably, the peptide proved more efficient than some well-known peptidase inhibitors, such as puromycin, leupeptin, and D-PAM. Additionally, Livagen and Epitalon inhibit enkephalin-degrading enzymes from human serum and interact with the endogenous opioid system.

Nucleolar Organizer Region Activity

Livagen increases the number of nucleolar organizer regions and nucleoli per cell. This activity is consistent with the peptide’s role in activating ribosomal genes and enhancing cellular synthetic capacity.

Why Is Livagen Studied in Switzerland?

Primarily, researchers study Livagen because it represents a well-characterized tetrapeptide bioregulator that enables investigation of chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying liver function, gene expression modulation, and cellular aging.

Research has demonstrated Livagen’s relevance across multiple domains. Livagen induces reactivation (deheterochromatinization) of chromatin to modify heterochromatinized chromosomal regions in cultured lymphocytes of aged individuals. Additionally, the peptide has demonstrated hepatoprotective and immunoprotective properties in animal models.

Furthermore, researchers have studied Livagen for its anti-aging properties and its ability to correct genomic instability. Studies have examined the effects of Livagen on activity of digestive enzymes in the gastrointestinal tract and non-digestive organs in rats of different ages. Additionally, researchers have evaluated the peptide for its protective action in relation to radiation-induced adaptive response and genomic instability in atherosclerosis. Ultimately, researchers who buy Livagen 20mg in Switzerland gain access to a comprehensive research tool for investigating chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation.

Livagen Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
Chromatin Remodeling	Deheterochromatinization, ribosomal gene activation, epigenetic regulation	Mechanistic / In Vitro
Hepatic Gene Regulation	Liver tissue-specific gene expression, hepatocyte protein synthesis	Mechanistic / In Vitro
Liver Research	Hepatocyte function, hepatoprotection, liver fibrosis models	Animal / Preclinical
Immunomodulation	Lymphocyte chromatin activation, immune system support	Mechanistic / In Vitro
Anti-Aging Research	Age-related chromatin condensation, cellular senescence reversal	Preclinical
Enzyme Inhibition Studies	Enkephalin-degrading enzymes, peptidase inhibition	Mechanistic / In Vitro
Genomic Stability	Radiation-induced adaptive response, genomic instability correction	Preclinical

Livagen Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
Livagen (KEDA)	Liver tissue, chromatin remodeling, hepatic gene regulation	Chromatin decondensation, ribosomal gene activation	Tetrapeptide; Lys-Glu-Asp-Ala sequence; liver-specific bioregulator
Epithalon (AEDG)	Pineal gland, aging, circadian rhythms	DNA interaction, telomerase activation	Different target tissue; Ala-Glu-Asp-Gly sequence
Cortagen (AEDP)	Brain and CNS, neuroprotection, nerve regeneration	Chromatin remodeling, gene expression modulation	Different target tissue; Ala-Glu-Asp-Pro sequence
Vilon (KE)	Immune system, thymus	DNA interaction, immune modulation	Dipeptide; shares Lys-Glu with Livagen; immunomodulatory

Comparatively, Livagen differs from other Khavinson peptide bioregulators in its tissue specificity and amino acid sequence. On the one hand, Livagen (Lys-Glu-Asp-Ala) is specifically designed for liver tissue research, with demonstrated effects on hepatocyte protein synthesis, chromatin decondensation, and hepatic gene regulation. On the other hand, Epithalon (Ala-Glu-Asp-Gly) targets pineal gland function and aging-related processes, while Cortagen (Ala-Glu-Asp-Pro) focuses on brain and central nervous system research. In contrast, Vilon (Lys-Glu) is a dipeptide with primarily immunomodulatory properties and shares the Lys-Glu sequence with Livagen.

Research Applications for Livagen in Switzerland

Scientists have investigated Livagen across several research domains:

• Chromatin and Epigenetic Research: Researchers use Livagen to study chromatin decondensation, ribosomal gene activation, and epigenetic regulation in lymphocyte and hepatocyte cultures.
• Hepatic Gene Expression Studies: Investigations have explored Livagen’s effects on hepatocyte protein synthesis and liver tissue-specific gene expression.
• Liver Research: Livagen has been studied for its hepatoprotective properties and its effects on liver function in preclinical models.
• Immunomodulation Studies: The peptide serves as a tool for investigating lymphocyte chromatin activation and immune system support.
• Anti-Aging Research: Studies have examined Livagen’s ability to reverse age-related chromatin condensation and cellular senescence.
• Enzyme Inhibition Research: Livagen has been investigated for its inhibition of enkephalin-degrading enzymes.

Evidently, researchers who buy Livagen 20mg in Switzerland gain a valuable addition to any laboratory toolkit focused on chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation.

Livagen Product Specifications

Specification	Details
Product Name	Livagen (KEDA)
Alternative Names	KEDA, Lys-Glu-Asp-Ala, Liver bioregulator peptide
Amount	20mg
Form	Lyophilized powder (white to off-white)
Purity	Not verified (≥98.5-99% HPLC purity reported by some suppliers)
Amino Acid Sequence	H-Lys-Glu-Asp-Ala-OH (KEDA)
Sequence (3-letter)	Lys-Glu-Asp-Ala
Peptide Length	4 amino acids (tetrapeptide)
Molecular Formula	C₁₈H₃₁N₅O₉
Molecular Weight	461.47 g/mol
CAS Number	195875-84-4 (reported by some suppliers)
Research Category	Healing & Regeneration / Anti-Aging & Longevity
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and buffered aqueous solutions

How to Evaluate Livagen Quality for Research

When sourcing Livagen peptide for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the compound’s molecular weight (461.47 g/mol) and sequence (H-Lys-Glu-Asp-Ala-OH).
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results including HPLC purity and identity confirmation.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount (20mg), sequence, molecular formula, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptides and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptide they are using in their laboratory investigations.

Storage and Stability of Livagen

Core Peptides supplies Livagen as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Weigh under dry conditions; the peptide is hygroscopic
• Reconstitute only immediately before use with appropriate sterile solvents (sterile water or buffered aqueous solutions)
• Inject solvent slowly against the inner wall of the vial; avoid vigorous agitation during dissolution
• Filter sterilize if required (e.g., 0.22 µm) immediately prior to use
• Aliquot and store reconstituted solutions at -20°C or below to minimize degradation
• Protect from light and moisture; prolonged exposure to light, elevated temperature, or aqueous environments may reduce stability

Frequently Asked Questions About Buying Livagen 20mg in Switzerland

What is Livagen?

Specifically, Livagen (KEDA) is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (KEDA). It is a tissue-specific bioregulator developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted bioregulator.

What is Livagen researched for?

Primarily, researchers study Livagen for its role in chromatin remodeling, hepatic gene regulation, and tissue-specific bioregulation. Studies have investigated its effects on chromatin decondensation, ribosomal gene activation, hepatocyte protein synthesis, and hepatoprotective mechanisms.

How does Livagen work?

Mechanistically, Livagen functions through epigenetic chromatin remodeling, inducing de-heterochromatinization and activating ribosomal gene expression. It modulates gene expression in hepatic and lymphocyte systems through tissue-specific regulation and exhibits hepatoprotective and immunoprotective properties.

What is the amino acid sequence of Livagen?

The amino acid sequence is H-Lys-Glu-Asp-Ala-OH (KEDA).

What is the molecular weight of Livagen?

The molecular weight is 461.47 g/mol.

What is the molecular formula of Livagen?

The molecular formula is C₁₈H₃₁N₅O₉.

Is Livagen synthetic?

Yes, Livagen is a synthetic peptide produced through solid-phase peptide synthesis.

How does Livagen differ from Vilon?

Livagen (Lys-Glu-Asp-Ala) is a tetrapeptide that shares the first two amino acids (Lys-Glu) with Vilon (KE), a dipeptide. While Vilon has primarily immunoprotective properties, Livagen has broader hepatoprotective and chromatin-modulating activities.

What evidence exists for Livagen?

Research on Livagen includes studies demonstrating chromatin decondensation in lymphocytes from elderly individuals, ribosomal gene activation, hepatocyte protein synthesis enhancement, inhibition of enkephalin-degrading enzymes, and hepatoprotective effects in animal models. All published research on Livagen originates from Khavinson’s group and collaborating institutions in Russia and Georgia.

Is Livagen approved as a medicine?

No. Regulatory authorities have not approved Livagen as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is Livagen intended for human use?

No. Livagen is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy Livagen 20mg in Switzerland?

You can buy Livagen 20mg in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate Livagen quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in Livagen may also find the following related compounds relevant to their work:

• Vilon — A related Khavinson dipeptide (Lys-Glu) researched for immune system modulation and thymus function.
• Epithalon — A related Khavinson tetrapeptide (Ala-Glu-Asp-Gly) researched for pineal gland function, aging, and telomerase activation.
• Cortagen — A related Khavinson tetrapeptide (Ala-Glu-Asp-Pro) researched for brain and nervous system tissue.
• Bronchogen — A related Khavinson tetrapeptide (Ala-Glu-Asp-Leu) researched for bronchial epithelium and pulmonary tissue.

Explore Healing & Regeneration

Livagen belongs to the Healing & Regeneration category of research compounds. Healing & Regeneration products are studied for their potential roles in tissue repair, cellular regeneration, and tissue-specific bioregulation. Generally, researchers who buy Livagen 20mg in Switzerland often pair it with related compounds in this category to explore complementary pathways in hepatic regeneration and tissue-specific research.

Explore Anti-Aging & Longevity

Researchers studying age-related chromatin changes, cellular senescence, and tissue-specific bioregulation may also find relevant compounds in the Anti-Aging & Longevity category. Livagen’s effects on chromatin decondensation and ribosomal gene activation make it a valuable tool for investigating age-related changes in gene expression and cellular function.

Further Research

For researchers seeking to deepen their understanding of Livagen and its research applications, the following areas may warrant further investigation:

• The relationship between Livagen-mediated chromatin decondensation and specific downstream gene expression changes in hepatocytes and lymphocytes
• Comparative studies between Livagen and other Khavinson peptides in various hepatic and tissue-specific models
• The potential role of Livagen in modulating age-related chromatin condensation and cellular senescence
• Mechanistic studies on Livagen’s interaction with DNA and chromatin and its functional consequences for gene transcription
• Exploration of Livagen’s effects on different cell types and tissue systems beyond the liver and lymphocytes

Research Disclaimer

Livagen is a research peptide supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptides should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.